Sources of vascular nitric oxide and reactive oxygen species and their regulation

J Tejero, S Shiva, MT Gladwin - Physiological reviews, 2019 - journals.physiology.org
Nitric oxide (NO) is a small free radical with critical signaling roles in physiology and
pathophysiology. The generation of sufficient NO levels to regulate the resistance of the …

Genomics of hypertension: the road to precision medicine

S Padmanabhan, AF Dominiczak - Nature Reviews Cardiology, 2021 - nature.com
The known genetic architecture of blood pressure now comprises> 30 genes, with rare
variants resulting in monogenic forms of hypertension or hypotension and> 1,477 common …

Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial

PW Armstrong, CSP Lam, KJ Anstrom, J Ezekowitz… - Jama, 2020 - jamanetwork.com
Importance Patients with heart failure and preserved ejection fraction (HFpEF) are at high
risk of mortality, hospitalizations, and reduced functional capacity and quality of life …

Epidemiology and treatment of pulmonary arterial hypertension

EMT Lau, E Giannoulatou, DS Celermajer… - Nature Reviews …, 2017 - nature.com
In the past 2 decades, major changes have occurred in the epidemiological and treatment
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …

Vericiguat in patients with heart failure and reduced ejection fraction

PW Armstrong, B Pieske, KJ Anstrom… - … England Journal of …, 2020 - Mass Medical Soc
Background The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in
patients with heart failure and reduced ejection fraction who had recently been hospitalized …

Strategies to increase nitric oxide signalling in cardiovascular disease

JO Lundberg, MT Gladwin, E Weitzberg - Nature reviews Drug …, 2015 - nature.com
Nitric oxide (NO) is a key signalling molecule in the cardiovascular, immune and central
nervous systems, and crucial steps in the regulation of NO bioavailability in health and …

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension

HA Ghofrani, AM D'Armini, F Grimminger… - … England Journal of …, 2013 - Mass Medical Soc
Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …

Riociguat for the treatment of pulmonary arterial hypertension

HA Ghofrani, N Galiè, F Grimminger… - … England Journal of …, 2013 - Mass Medical Soc
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2
trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …

Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote …

P Ferdinandy, DJ Hausenloy, G Heusch… - Pharmacological …, 2014 - ASPET
Pre-, post-, and remote conditioning of the myocardium are well described adaptive
responses that markedly enhance the ability of the heart to withstand a prolonged …

Pulmonary hypertension due to left heart diseases

JL Vachiéry, Y Adir, JA Barberà, H Champion… - Journal of the American …, 2013 - jacc.org
Pulmonary hypertension (PH), a common complication of left heart diseases (LHD),
negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence …